Wei Li
机构：Third Affiliated Hospital of Zhengzhou University, Zhengzhou People's Hospital · ORCID：0000-0001-5550-508X
发表论文 181 篇 · 总被引 3136 次 · h-index 32
代表论文
- Sacituzumab govitecan in HR+HER2− metastatic breast cancer: the randomized phase 3 EVER-132-002 trial (2024 · Nature Medicine · 被引 44)
- Increased Expression of VCAM1 on Brain Endothelial Cells Drives Blood–Brain Barrier Impairment Following Chronic Cerebral Hypoperfusion (2024 · ACS Chemical Neuroscience · 被引 35)
- ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer (2025 · Signal Transduction and Targeted Therapy · 被引 29)
- Multivalent DNA lysosome-targeting chimaera for targeted protein degradation and inhibition of c-Met signaling pathways (2025 · Chemical Engineering Journal · 被引 5)
- Arntl-induced upregulation of DUSP1 inhibits tumor progression in esophageal squamous cell carcinoma by inactivating ERK signaling (2024 · Cancer Biology & Therapy · 被引 5)
- Selective inhibition of c-Met signaling pathways with a bispecific DNA nanoconnector for the targeted therapy of cancer (2024 · International Journal of Biological Macromolecules · 被引 4)